Evommune Inc. (EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, has a pair of clinical trial catalysts to watch in the coming months.
The company has two investigational drugs in clinical development, namely EVO756 and EVO301.
EVO756: Oral MRGPRX2 Blocker
EVO756, an oral drug, works by blocking Mas-Related G-Protein Coupled Receptor X2 (MRGPRX2), which is highly expressed on mast cells and peripheral neurons. MRGPRX2 is a promising target for therapeutics addressing conditions like chronic urticaria, atopic dermatitis, and severe asthma.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.